Search clinical trials for: SEP-225289

Total 1783 results

Sunovion

Completed

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
Sunovion

Completed

Adult Attention Deficit Hyperactivity Disorder

Adult Attention Deficit Hyperactivity Disorder

United States
Sunovion

Completed

Dasotraline Pediatric ADHD Study

Attention Deficit Hyperactivity Disorder

United States
Sunovion

Completed

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
Polish Mother Memorial Hospital Research Institute

Completed

The Impact of Positioning on Bottle-feeding in Preterm Infants. A Comparative Study PMMHHRI-2018/V/9-SZB

Bottle Feeding | Premature

Poland
KU Leuven

Completed

Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial

Irritable Bowel Syndrome (IBS)

Belgium, Netherlands
Augusta University

Completed

Mechanism of Action of Biofeedback Therapy

Hypersensitivity | Constipation | Hyposensitivity

United States
University of Trieste
Cliniche Humanitas Gavazzeni; A.O.U. Città della Salute e della Scienza - Molinette...

Unknown

SAP Versus ESP Block in Multimodal Pain Management in Mini-invasive Thoracic Surgery: an Observational Prospective Multicentric Study

Pain, Postoperative | SAP Block Versus ESP Block | Evaluation of Locoregional Techniques | Multimodal Pain Management

Italy
University Hospital, Basel, Switzerland

Completed

Feasibility and Reliability of Multimodal Evoked Potentials (EP-B)

Multiple Sclerosis

Switzerland
Anna Uskova

Withdrawn

Erector Spinae Plane Block vs Erector Spinae Plane Block With Serratus Anterior Plane Block in Thoracic Surgery

Pain, Postoperative

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients (Agility)

Melanoma

Italy
Medipol University

Completed

Erector Spinae Plane Block or Serratus Anterior Plane (SAP) Block Following Video Assisted Thoracic Surgery

Lung Diseases

Turkey
Klinikum St. Georg gGmbH

Completed

Trigeminus-evoked Somatosensory Potentials in Patients Undergoing Carotid Surgery (TRISEP)

Carotid Surgery

Germany
University of East Anglia

Unknown

Exercise Prior to Oesophagectomy (ExPO)

Oesophageal Adenocarcinoma | Postoperative Complications (Cardiopulmonary)

United Kingdom
Sumitomo Pharma America, Inc.

Completed

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Schizophrenia

United States, Serbia, Croatia, Bulgaria, Latvia, Russian Federation, Ukraine
Sunovion

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (SEP-363856)

Schizophrenia

United States
Universidade Federal Fluminense

Active, not recruiting

Clinical Evaluation of Bulk Fill Composite Restorations Associated to Universal Adhesive System (FBFSBU)

Dental Restoration Failure of Marginal Integrity

Brazil
Sumitomo Pharma America, Inc.

Completed

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Schizophrenia

United States, Serbia, Colombia, Bulgaria, Russian Federation, Ukraine
Sunovion

Completed

A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

Depressive Episode | Bipolar 1 Depression

Japan, Serbia, United States, Poland, Russian Federation, Bulgaria, Slovakia, Ukraine
Universidade Estadual de Ponta Grossa
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

Completed

BONDING TO ENAMEL USING A UNIVERSAL ADHESIVE (RCT)

Clinical Trial

Brazil
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Schizophrenia

Japan, Taiwan, China, Philippines
i-SEP

Completed

Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery (i-TRANSEP)

Hemorrhage | Blood Loss | Surgical Blood Loss

France
Sumitomo Pharma America, Inc.

Terminated

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Depressive Episodes, Bipolar I Depression

United States, Bulgaria, Japan, Romania, Canada, Slovakia
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Schizophrenia

Japan
Sumitomo Pharma America, Inc.

Terminated

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

Schizophrenia

United States, Serbia, Ukraine, Croatia, Colombia, Russian Federation, Bulgaria, Latvia
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

Schizophrenia

Japan
Sunovion

Completed

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

Schizophrenia

United States, Ukraine, Russian Federation, Hungary, Romania
Sunovion

Completed

A Safety, Efficacy and Tolerability Study of SEP-225289

Depressive Disorder, Major

United States
Sumitomo Pharma America, Inc.

Completed

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Terminated

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

Depressive Episodes, Bipolar I Depression

United States, Bulgaria, Japan
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Schizophrenia

Japan
Sunovion

Completed

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Recruiting

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States, Spain, Japan, Bulgaria, Estonia, Finland, Slovakia, Sweden
Sunovion

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis

United States
Fundació Institut Germans Trias i Pujol
Fundació La Marató de TV3

Completed

PROMISE (Somatosensory Evoked POtEntials MonItoring During Acute Ischemic StrokE) Study (PROMISE)

Acute Cerebrovascular Accident | Endovascular Procedures

Spain
Sunovion

Completed

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

Schizophrenia

Hungary, United States, Romania, Ukraine, Russian Federation
University of Arizona
Arizona Biomedical Research Commission (ABRC)

Unknown

Sleep Promotion in Critically Ill and Injured Patients Cared for in the Intensive Care Unit

Sleep Deprivation

United States
Babes-Bolyai University

Completed

Effectiveness of the Social-Emotional Prevention Program Enhanced Version (SEP+)

Child Behavior Problem

Romania
Sunovion

Completed

A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects

Healthy

United States
Otsuka Pharmaceutical Development & Commercialization...
Sumitomo Pharma Co., Ltd.; Sumitomo Pharma America, Inc.

Recruiting

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
University of Bologna

Completed

Postural Re-education in Low Back Pain

Low Back Pain

Italy
Hull University Teaching Hospitals NHS Trust
University of Hull

Completed

Trial of Nonsurgical Treatment of Intermittent Claudication Due to Femoro-popliteal Disease

Intermittent Claudication | Femoropopliteal Disease

United Kingdom
The University of Texas Health Science Center at...
Alzheimer's Association; The Claude D. Pepper Older Americans Independence... and other collaborators

Completed

Stress-Busting Program and QoL, Bio-markers of Immunity/Stress and Cellular Aging

Stress, Psychological | Stress, Physiological | Telomere Shortening

United States
Riphah International University

Recruiting

Effects of Speed Endurance Training on Agility and Functional Performance in Soccer Players

Sports Physical Therapy

Pakistan
University of Belgrade

Completed

Effect of Injectable Platelet-Rich Fibrin (i-PRF) in Initial Treatment of Chronic Periodontitis (EIPRFITCP)

Periodontitis

Serbia
Cephalon

Completed

Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis

Psoriasis

United States
Edgard Costa de Vilhena
Amparo Maternal Maternidade Social

Completed

Homeopathic Medication and Nutritional Oriented Diet to Treat Overweight Pregnant Women With Mental Disorder

Overweight | Pregnancy | Mental Disorder

Brazil
Sumitomo Pharma America, Inc.

Active, not recruiting

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Enrolling by invitation

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

Schizophrenia

United States
The George Institute
Changhai Hospital; University of Calgary

Not yet recruiting

Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial (ENCHANTED3/MT)

Ischemic Stroke, Acute

3

Subscribe